MCKESSON CORPORATION (MCK) is expected to report Q4 earnings on Monday, January 30, before the market open.
(Click chart to expand)
For fiscal year 2012, analysts estimate that MCK will earn $6.32. For the 2nd quarter of fiscal year 2012, MCK announced earnings per share of $1.20, representing 19% of the total annual estimate. For fiscal year 2013, analysts estimate that MCK's earnings per share will grow by 10% to $6.96. MCK's current quarter consensus estimate has decreased over the past 90 days from 1.52 to 1.37, a loss of -.6%. Consensus estimates for the Generic & Specialty Pharma Industry have moved an average 0.0% during the same time period. The consensus range is between $1.28 and $1.52 according to 17 analysts reviewed. Of the past four earnings reports, MCK had four positive surprise reports of 9.4%, 3.6%, 11.5%, and 16.8% respectively. A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation.
On 01/24/12, MCK closed at $76.55, 12.3% below its 52- week high and 14.9% above its 52-week low. MCK shares are currently trading 2.5% below their 50-day moving average of $78.48, and 3.8% below their 200-day moving average of $79.57. Despite the minor sell-off analysts believe the 12-month target price is $100. This is derived by applying an approximate peer-level 15.7X multiple to the 2012 cash EPS estimate of $6.32. In December 2010, MCK acquired US Oncology, a leading provider of products and services to oncologists, for $2.1 billion in cash and I believe this has put it at an advantageous position for growth that it is currently experiencing. I believe this earnings report will be another positive, and five positives in a row cannot be ignored. I believe this stock is poised for growth, especially after the earnings report.